Acute kidney injury medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Acute kidney injury}} {{CMG}}; {{AE}} ==Overview== There is no treatment for [disease name]; the mainstay of therapy is supportive care. OR Supportive therapy f...")
 
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute kidney injury}}
{{Acute kidney injury}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{F.K}}


==Overview==
==Overview==
There is no treatment for [disease name]; the mainstay of therapy is supportive care.


OR
Pharmacologic medical therapies for acute kidney injury include  supportive therapy, [[diuretics]], correction of [[hyperglycemia]].
 
==Medical Therapy==
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
*Pharmacologic medical therapies for acute kidney injury include  supportive therapy, [[diuretics]], correction of [[hyperglycemia]].
 
===Acute Kidney Injury===
OR
====Supportive Therapy====
 
* Although the [[pathogenesis]] of AKI often involves volume depletion especially in the context of prerenal [[azotemia]], no trials have assessed the efficacy of fluids vs. placebo in preventing and treating AKI.
The majority of cases of [disease name] are self-limited and require only supportive care.
* The response to fluid [[resuscitation]] in AKI is very variable with studies showing that a positive balance is sometimes associated with higher mortality.<ref name="pmid18533029">{{cite journal| author=Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL et al.| title=A positive fluid balance is associated with a worse outcome in patients with acute renal failure. | journal=Crit Care | year= 2008 | volume= 12 | issue= 3 | pages= R74 | pmid=18533029 | doi=10.1186/cc6916 | pmc=PMC2481469 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533029 }} </ref>
 
* This is true especially if the therapeutic window for treatment is missed and the in impairment progresses into a volume non-responsive AKI.<ref name="pmid18354074">{{cite journal| author=Himmelfarb J, Joannidis M, Molitoris B, Schietz M, Okusa MD, Warnock D et al.| title=Evaluation and initial management of acute kidney injury. | journal=Clin J Am Soc Nephrol | year= 2008 | volume= 3 | issue= 4 | pages= 962-7 | pmid=18354074 | doi=10.2215/CJN.04971107 | pmc=PMC2440262 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18354074 }} </ref>
OR
* Still, it is commonly agreed that fluid [[resuscitation]] is important to limit the extend of kidney injury and possibly facilitate recovery of renal function.
 
* Early fluid [[resuscitation]] is key especially in patients with severe [[hypotension]] (e.g: septic shock).
[Disease name] is a medical emergency and requires prompt treatment.
* However, the amount and duration of volume expansion has not been well elaborated.
 
* A recent protocolized approach to septic shock known as Early Goal-Directed Therapy (EGDT)has gained wide acceptance.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 |pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html }} </ref>
OR
* The protocol aims to recognize septic shock early on and initiates [[resuscitation]] with the aim of reestablishing tissue perfusion in 6 hours.
 
* Goals are:<ref name="pmid11794169">{{cite journal| author=Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al.| title=Early goal-directed therapy in the treatment of severe sepsis and septic shock. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 19 | pages= 1368-77 | pmid=11794169 | doi=10.1056/NEJMoa010307 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11794169 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11985431 Review in: ACP J Club. 2002 May-Jun;136(3):90] </ref>
The mainstay of treatment for [disease name] is [therapy].
# Return of mean arterial blood pressure to >65mm Hg
 
# Central venous pressure between 8-12mm Hg
OR
# Improvement in blood [[lactate]] levels
 
# Central venous [[oxygen saturation]] (ScvO<sub>2</sub>)>70%
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
# [[Urine output]] of >0.5 ml/kg/h
 
* Selection of the appropriate fluid types for resuscitation is also important for outcome. Isotonic saline (0.9%) is the standard of care for volume expansion due to the lack of support showing that colloids are a superior option.
OR
* The Saline vs. Albumin Fluid Evaluation (SAFE) study, showed that albumin resuscitation is safe although doesn't have any added benefit over [[normal saline]].<ref name="pmid15163774‎">{{cite journal| author=Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R et al.| title=A comparison of albumin and saline for fluid resuscitation in the intensive care unit. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 22 | pages= 2247-56 | pmid=15163774‎ | doi=10.1056/NEJMoa040232 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15163774 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341449 Review in: ACP J Club. 2004 Sep-Oct;141(2):29] </ref>
 
* [[Hydroxyethylstarch]] is not a safe option for the concerns of coagulopathy, osmotic nephrosis especially with [[hypertonic]] HES, and increased AKI and 90 day mortality.<ref name="pmid11289347">{{cite journal| author=Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F et al.| title=Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. | journal=Lancet | year= 2001 | volume= 357 | issue= 9260 | pages= 911-6 | pmid=11289347 | doi=10.1016/S0140-6736(00)04211-2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11289347 }} </ref>
[Therapy] is recommended among all patients who develop [disease name].
* [[Vasopressors]] are also important in the management of patients with sepsis and septic shock with hypotension refractory to fluid expansion.
 
* Clinical data is insufficient to differentiate between different [[vasopressors]], although commonly used agents are [[norepinephrine]], [[dopamine]] and [[vasopressin]] especially in patients unresponsive to [[norepinephrine]].<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 |pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html }} </ref>
OR
* Other than appropriate fluid balance and volume resuscitation, correction of electrolyte imbalances particularly hyperkalemia and metabolic acidosis are important.
 
* Drugs should be monitored for any possible [[nephrotoxicity]] to prevent any aggravation of renal dysfunction. Drug doses should also be altered to follow the decline in eGFR.
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
 
OR
 
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
 
OR


Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
====Diuretics====
 
* Loop diuretics in theory should help to improve AKI and prevent AKI in patients at risk. By inhibiting the Na/K/2Cl transporter they decrease oxygen consumption, and increase tubular fluids inducing a wash-out of necrotic debris.<ref name="pmid18636060‎">{{cite journal| author=Karajala V, Mansour W, Kellum JA| title=Diuretics in acute kidney injury. | journal=Minerva Anestesiol | year= 2009 | volume= 75 | issue= 5 | pages= 251-7 | pmid=18636060‎ | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18636060 }} </ref>
OR
* However, studies have shown that [[Furosemide|furosemid]]<nowiki/>e has no benefit and sometimes increases the risk of AKI.<ref name="pmid14575286‎">{{cite journal| author=Lombardi R, Ferreiro A, Servetto C| title=Renal function after cardiac surgery: adverse effect of furosemide. | journal=Ren Fail | year= 2003 | volume= 25 | issue= 5 | pages= 775-86 | pmid=14575286‎ | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14575286 }} </ref><ref name="pmid10616845‎">{{cite journal| author=Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M| title=Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. | journal=J Am Soc Nephrol | year= 2000 | volume= 11 | issue= 1 | pages= 97-104 | pmid=10616845‎ | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10616845 }} </ref>
 
* For that, it is recommended not to use [[diuretics]] to prevent or treat AKI except in cases of fluid overload where enhanced [[diuresis]] is required.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 |pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html }} </ref>
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
 
==Medical Therapy==
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
===Disease Name===


* '''1 Stage 1 - Name of stage'''
====Correction of Hyperglycemia====
** 1.1 '''Specific Organ system involved 1'''
* Patients with AKI are usually in the critical care setting and are at high risk for developing stress hyperglycemia.
*** 1.1.1 '''Adult'''
* Hyperglycemia by itself has been associated with a higher risk of developing and maintaining AKI.<ref name="pmid16452557‎">{{cite journal| author=Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I et al.| title=Intensive insulin therapy in the medical ICU. | journal=N Engl J Med | year= 2006 | volume= 354 | issue= 5 | pages= 449-61 | pmid=16452557‎ | doi=10.1056/NEJMoa052521 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16452557 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16944854 Review in: ACP J Club. 2006 Sep-Oct;145(2):34] </ref>
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
* Van den Berghe et al showed significant improvement in morbidity and mortality, as well as a decrease in AKI and need for RRT in the group of patients with tight [[glycemic]] control.<ref name="pmid11794168‎">{{cite journal| author=van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al.| title=Intensive insulin therapy in critically ill patients. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 19 | pages= 1359-67 | pmid=11794168‎ | doi=10.1056/NEJMoa011300 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11794168 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11995656 Review in: Evid Based Nurs. 2002 Apr;5(2):53] [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11985422 Review in: ACP J Club. 2002 May-Jun;136(3):81] </ref>
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
* Thomas et al. also found in a meta-analysis of clinical trials a 38% risk reduction of AKI in patients on tight glycemic control.<ref name="pmid17604310">{{cite journal| author=Thomas G, Rojas MC, Epstein SK, Balk EM, Liangos O, Jaber BL| title=Insulin therapy and acute kidney injury in critically ill patients a systematic review. | journal=Nephrol Dial Transplant | year= 2007 | volume= 22 | issue= 10 | pages= 2849-55 | pmid=17604310 | doi=10.1093/ndt/gfm401 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17604310 }} </ref>
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
* Thus, it is recommended that patients with AKI, especially those in the ICU setting, have their glucose levels monitored closely with insulin therapy in patients with hyperglycemia aiming at a plasma glucose between 110 and 149 mg/dL.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 |pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html }} </ref>
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
*** 1.1.2 '''Pediatric'''
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose) 
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
** 1.2 '''Specific Organ system involved 2'''
*** 1.2.1 '''Adult'''
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
*** 1.2.2  '''Pediatric'''
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)


* 2 '''Stage 2 - Name of stage'''
====Contraindicated Medications====
** 2.1 '''Specific Organ system involved 1 '''
{{MedCondContrAbs|MedCond = Renal failure with electrolyte imbalance|Diclofenamide|Spironolactone|Aminosalicylic acid}}
**: '''Note (1):'''
{{MedCondContrAbs|MedCond = Severe Renal failure (creatinine clearance (CrCl) < 30ml/min)|Danazol|Fondaparinux|Sulfamethoxazole/Trimethoprim (oral)}}
**: '''Note (2)''':
{{MedCondContrAbs|MedCond = Renal impairment (e.g., serum creatinine ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or abnormal creatinine clearance)|Linagliptin and Metformin hydrochloride|Metformin|Saxagliptin hydrochloride and Metformin hydrochloride}}
**: '''Note (3):'''
{{MedCondContrAbs|MedCond = Renal impairment|Drospirenone and Ethinyl estradiol}}
*** 2.1.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.1.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)


==References==
==References==

Latest revision as of 16:32, 27 July 2018

Acute kidney injury Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute Kidney Injury from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute kidney injury medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute kidney injury medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute kidney injury medical therapy

CDC on Acute kidney injury medical therapy

Acute kidney injury medical therapy in the news

Blogs on Acute kidney injury medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Acute kidney injury medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]

Overview

Pharmacologic medical therapies for acute kidney injury include supportive therapy, diuretics, correction of hyperglycemia.

Medical Therapy

  • Pharmacologic medical therapies for acute kidney injury include supportive therapy, diuretics, correction of hyperglycemia.

Acute Kidney Injury

Supportive Therapy

  • Although the pathogenesis of AKI often involves volume depletion especially in the context of prerenal azotemia, no trials have assessed the efficacy of fluids vs. placebo in preventing and treating AKI.
  • The response to fluid resuscitation in AKI is very variable with studies showing that a positive balance is sometimes associated with higher mortality.[1]
  • This is true especially if the therapeutic window for treatment is missed and the in impairment progresses into a volume non-responsive AKI.[2]
  • Still, it is commonly agreed that fluid resuscitation is important to limit the extend of kidney injury and possibly facilitate recovery of renal function.
  • Early fluid resuscitation is key especially in patients with severe hypotension (e.g: septic shock).
  • However, the amount and duration of volume expansion has not been well elaborated.
  • A recent protocolized approach to septic shock known as Early Goal-Directed Therapy (EGDT)has gained wide acceptance.[3]
  • The protocol aims to recognize septic shock early on and initiates resuscitation with the aim of reestablishing tissue perfusion in 6 hours.
  • Goals are:[4]
  1. Return of mean arterial blood pressure to >65mm Hg
  2. Central venous pressure between 8-12mm Hg
  3. Improvement in blood lactate levels
  4. Central venous oxygen saturation (ScvO2)>70%
  5. Urine output of >0.5 ml/kg/h
  • Selection of the appropriate fluid types for resuscitation is also important for outcome. Isotonic saline (0.9%) is the standard of care for volume expansion due to the lack of support showing that colloids are a superior option.
  • The Saline vs. Albumin Fluid Evaluation (SAFE) study, showed that albumin resuscitation is safe although doesn't have any added benefit over normal saline.[5]
  • Hydroxyethylstarch is not a safe option for the concerns of coagulopathy, osmotic nephrosis especially with hypertonic HES, and increased AKI and 90 day mortality.[6]
  • Vasopressors are also important in the management of patients with sepsis and septic shock with hypotension refractory to fluid expansion.
  • Clinical data is insufficient to differentiate between different vasopressors, although commonly used agents are norepinephrine, dopamine and vasopressin especially in patients unresponsive to norepinephrine.[3]
  • Other than appropriate fluid balance and volume resuscitation, correction of electrolyte imbalances particularly hyperkalemia and metabolic acidosis are important.
  • Drugs should be monitored for any possible nephrotoxicity to prevent any aggravation of renal dysfunction. Drug doses should also be altered to follow the decline in eGFR.

Diuretics

  • Loop diuretics in theory should help to improve AKI and prevent AKI in patients at risk. By inhibiting the Na/K/2Cl transporter they decrease oxygen consumption, and increase tubular fluids inducing a wash-out of necrotic debris.[7]
  • However, studies have shown that furosemide has no benefit and sometimes increases the risk of AKI.[8][9]
  • For that, it is recommended not to use diuretics to prevent or treat AKI except in cases of fluid overload where enhanced diuresis is required.[3]

Correction of Hyperglycemia

  • Patients with AKI are usually in the critical care setting and are at high risk for developing stress hyperglycemia.
  • Hyperglycemia by itself has been associated with a higher risk of developing and maintaining AKI.[10]
  • Van den Berghe et al showed significant improvement in morbidity and mortality, as well as a decrease in AKI and need for RRT in the group of patients with tight glycemic control.[11]
  • Thomas et al. also found in a meta-analysis of clinical trials a 38% risk reduction of AKI in patients on tight glycemic control.[12]
  • Thus, it is recommended that patients with AKI, especially those in the ICU setting, have their glucose levels monitored closely with insulin therapy in patients with hyperglycemia aiming at a plasma glucose between 110 and 149 mg/dL.[3]

Contraindicated Medications

Renal failure with electrolyte imbalance is considered an absolute contraindication to the use of the following medications:

Severe Renal failure (creatinine clearance (CrCl) < 30ml/min) is considered an absolute contraindication to the use of the following medications:

Renal impairment (e.g., serum creatinine ≥1.5 mg/dL for men, ≥1.4 mg/dL for women, or abnormal creatinine clearance) is considered an absolute contraindication to the use of the following medications:

Renal impairment is considered an absolute contraindication to the use of the following medications:

References

  1. ↑ Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL; et al. (2008). "A positive fluid balance is associated with a worse outcome in patients with acute renal failure". Crit Care. 12 (3): R74. doi:10.1186/cc6916. PMC 2481469. PMID 18533029.
  2. ↑ Himmelfarb J, Joannidis M, Molitoris B, Schietz M, Okusa MD, Warnock D; et al. (2008). "Evaluation and initial management of acute kidney injury". Clin J Am Soc Nephrol. 3 (4): 962–7. doi:10.2215/CJN.04971107. PMC 2440262. PMID 18354074.
  3. ↑ 3.0 3.1 3.2 3.3 Kidney Disease Improving Global Outcomes Work Group (2012). "2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury". Kidey Int Supp. 2: 69–88. doi:10.1038/kisup.2011.34.
  4. ↑ Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B; et al. (2001). "Early goal-directed therapy in the treatment of severe sepsis and septic shock". N Engl J Med. 345 (19): 1368–77. doi:10.1056/NEJMoa010307. PMID 11794169. Review in: ACP J Club. 2002 May-Jun;136(3):90
  5. ↑ Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; et al. (2004). "A comparison of albumin and saline for fluid resuscitation in the intensive care unit". N Engl J Med. 350 (22): 2247–56. doi:10.1056/NEJMoa040232. PMID 15163774‎ Check |pmid= value (help). Review in: ACP J Club. 2004 Sep-Oct;141(2):29
  6. ↑ Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F; et al. (2001). "Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study". Lancet. 357 (9260): 911–6. doi:10.1016/S0140-6736(00)04211-2. PMID 11289347.
  7. ↑ Karajala V, Mansour W, Kellum JA (2009). "Diuretics in acute kidney injury". Minerva Anestesiol. 75 (5): 251–7. PMID 18636060‎ Check |pmid= value (help).
  8. ↑ Lombardi R, Ferreiro A, Servetto C (2003). "Renal function after cardiac surgery: adverse effect of furosemide". Ren Fail. 25 (5): 775–86. PMID 14575286‎ Check |pmid= value (help).
  9. ↑ Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M (2000). "Lack of renoprotective effects of dopamine and furosemide during cardiac surgery". J Am Soc Nephrol. 11 (1): 97–104. PMID 10616845‎ Check |pmid= value (help).
  10. ↑ Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I; et al. (2006). "Intensive insulin therapy in the medical ICU". N Engl J Med. 354 (5): 449–61. doi:10.1056/NEJMoa052521. PMID 16452557‎ Check |pmid= value (help). Review in: ACP J Club. 2006 Sep-Oct;145(2):34
  11. ↑ van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M; et al. (2001). "Intensive insulin therapy in critically ill patients". N Engl J Med. 345 (19): 1359–67. doi:10.1056/NEJMoa011300. PMID 11794168‎ Check |pmid= value (help). Review in: Evid Based Nurs. 2002 Apr;5(2):53 Review in: ACP J Club. 2002 May-Jun;136(3):81
  12. ↑ Thomas G, Rojas MC, Epstein SK, Balk EM, Liangos O, Jaber BL (2007). "Insulin therapy and acute kidney injury in critically ill patients a systematic review". Nephrol Dial Transplant. 22 (10): 2849–55. doi:10.1093/ndt/gfm401. PMID 17604310.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Acute_kidney_injury_medical_therapy&oldid=1485815"